Catherine Thieblemont Selected Research

Rituximab (Mabthera)

3/2024	Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study.
2/2024	IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma.
2/2024	Early complete response as a validated surrogate marker in extranodal marginal zone lymphoma systemic therapy.
1/2024	Obinutuzumab versus Rituximab in transplant-eligible Mantle cell lymphoma patients.
12/2023	Long-Term Follow-Up of Rituximab Maintenance in Young Patients With Mantle-Cell Lymphoma Included in the LYMA Trial: A LYSA Study.
11/2023	Phase 3 SELENE study: ibrutinib plus BR/R-CHOP in previously treated patients with follicular or marginal zone lymphoma.
11/2023	Predictive Value of Minimal Residual Disease for Efficacy of Rituximab Maintenance in Mantle Cell Lymphoma: Results From the European Mantle Cell Lymphoma Elderly Trial.
1/2023	High-Dose Cytarabine and Autologous Stem-Cell Transplantation in Mantle Cell Lymphoma: Long-Term Follow-Up of the Randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network.
1/2023	Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis.
12/2022	Outcomes of older patients with diffuse large B-cell lymphoma treated with R-CHOP: 10-year follow-up of the LNH03-6B trial.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Catherine Thieblemont Research Topics

Disease

55	Lymphoma (Lymphomas) 03/2024 - 12/2002
46	Neoplasms (Cancer) 04/2024 - 02/2003
41	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2023 - 09/2009
35	B-Cell Lymphoma (Lymphoma, B Cell) 05/2024 - 03/2005
31	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/2024 - 10/2005
13	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 01/2024 - 08/2010
12	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2024 - 01/2004
10	Infections 12/2023 - 02/2012
9	Disease Progression 01/2023 - 08/2012
7	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 02/2024 - 02/2003
6	Hodgkin Disease (Hodgkin's Disease) 11/2016 - 07/2004
5	Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral) 02/2024 - 09/2013
5	Cytokine Release Syndrome 01/2024 - 11/2020
5	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 02/2022 - 04/2004
5	Neutropenia 01/2022 - 05/2013
4	Residual Neoplasm 03/2024 - 03/2016
4	Hematologic Neoplasms (Hematological Malignancy) 01/2023 - 01/2013
3	Multiple Myeloma 06/2022 - 07/2004
3	Febrile Neutropenia 01/2022 - 04/2011
3	Lymphoproliferative Disorders (Lymphoproliferative Disorder) 01/2022 - 03/2005
3	Cytopenia 08/2014 - 06/2002
2	Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma) 02/2024 - 07/2014
2	Waldenstrom Macroglobulinemia (Macroglobulinemia) 01/2022 - 03/2005
2	Fever (Fevers) 01/2022 - 08/2012
2	COVID-19 12/2021 - 01/2020
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 07/2021 - 11/2015
2	Extranodal NK-T-Cell Lymphoma 01/2021 - 02/2011
2	Fatigue 01/2020 - 01/2019
2	Acute Kidney Injury (Acute Renal Failure) 10/2014 - 08/2013
2	Tumor Lysis Syndrome 10/2014 - 08/2013

Drug/Important Bio-Agent (IBA)

51	Rituximab (Mabthera)FDA Link 03/2024 - 01/2004
19	Chimeric Antigen ReceptorsIBA 11/2023 - 01/2020
15	Vincristine (Oncovin)FDA LinkGeneric 02/2024 - 03/2003
15	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2024 - 03/2003
15	Doxorubicin (Adriamycin)FDA LinkGeneric 02/2024 - 03/2003
14	Prednisone (Sone)FDA LinkGeneric 02/2024 - 03/2003
12	axicabtagene ciloleucelIBA 05/2024 - 11/2020
11	obinutuzumabIBA 01/2024 - 05/2012
10	Cytarabine (Cytosar-U)FDA LinkGeneric 01/2023 - 08/2010
9	Agammaglobulinaemia Tyrosine KinaseIBA 02/2024 - 08/2014
9	tisagenlecleucelIBA 01/2024 - 11/2020
9	ibrutinibIBA 11/2023 - 08/2014
8	Lenalidomide (CC 5013)FDA Link 01/2022 - 01/2012
6	Chlorambucil (Leukeran)FDA Link 02/2024 - 03/2003
6	Dexamethasone (Maxidex)FDA LinkGeneric 01/2023 - 08/2010
6	selinexorIBA 02/2022 - 07/2020
6	Monoclonal AntibodiesIBA 10/2016 - 12/2002
5	Bendamustine Hydrochloride FDA Link 03/2024 - 02/2017
5	Biomarkers (Surrogate Marker)IBA 10/2023 - 10/2020
5	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 11/2011
5	Proteins (Proteins, Gene)FDA Link 10/2019 - 04/2011
4	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2024 - 12/2015
4	Etoposide (VP 16)FDA LinkGeneric 01/2023 - 04/2011
4	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 03/2009
4	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2022 - 05/2013
4	Anti-Bacterial Agents (Antibiotics)IBA 10/2021 - 02/2003
3	romidepsin (FK228)FDA Link 02/2024 - 04/2015
3	tocilizumab (atlizumab)FDA Link 01/2024 - 01/2021
3	AntigensIBA 01/2023 - 04/2005
3	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 12/2022 - 01/2021
3	idelalisibIBA 02/2022 - 01/2018
3	Transcription Factors (Transcription Factor)IBA 02/2022 - 01/2020
3	Carboplatin (JM8)FDA LinkGeneric 01/2021 - 11/2011
3	Oxaliplatin (Eloxatin)FDA LinkGeneric 01/2021 - 08/2010
3	Immunoglobulins (Immunoglobulin)IBA 12/2018 - 03/2005
3	Ifosfamide FDA LinkGeneric 10/2016 - 04/2011
2	Brentuximab VedotinIBA 02/2024 - 07/2014
2	AntibodiesIBA 01/2024 - 10/2019
2	zanubrutinibIBA 11/2023 - 12/2021
2	brexucabtagene autoleucelIBA 10/2023 - 02/2021
2	InterferonsIBA 01/2023 - 01/2023
2	Vindesine (Vindesin)IBA 01/2023 - 12/2014
2	pembrolizumabIBA 01/2023 - 12/2019
2	NF-kappa B (NF-kB)IBA 02/2022 - 01/2020
2	Histone Deacetylase InhibitorsIBA 01/2022 - 04/2015
2	Immunoglobulin M (IgM)IBA 01/2022 - 03/2005
2	Methotrexate (Mexate)FDA LinkGeneric 04/2021 - 02/2011
2	Antiviral Agents (Antivirals)IBA 01/2020 - 03/2015
2	Asparaginase (Elspar)FDA Link 01/2019 - 02/2011
2	OTX015IBA 04/2016 - 03/2016
2	Histones (Histone)IBA 01/2016 - 04/2011
2	Bleomycin (Blenoxane)FDA LinkGeneric 12/2014 - 04/2011
2	rasburicase (Elitek)FDA Link 10/2014 - 08/2013
2	tipifarnib (R115777)IBA 03/2010 - 04/2008
2	Farnesyltranstransferase (Farnesyltransferase)IBA 03/2010 - 04/2008
1	Indicators and Reagents (Reagents)IBA 04/2024
1	Glucose (Dextrose)FDA LinkGeneric 04/2024

Therapy/Procedure

64	Therapeutics 05/2024 - 12/2002
31	Stem Cell Transplantation 05/2024 - 10/2005
20	Drug Therapy (Chemotherapy) 02/2024 - 12/2002
6	Transplantation 01/2022 - 01/2017
5	Radiotherapy 11/2023 - 11/2011
5	Splenectomy 12/2018 - 06/2002
4	Immunotherapy 01/2023 - 12/2018
3	Hematopoietic Stem Cell Transplantation 01/2021 - 08/2012
2	Chemoradiotherapy 01/2023 - 08/2016
2	Aftercare (After-Treatment) 09/2022 - 10/2021
2	Combination Drug Therapy (Combination Chemotherapy) 01/2021 - 08/2010
2	Induction Chemotherapy 11/2020 - 01/2020
2	Salvage Therapy 11/2011 - 08/2010